News

Video

Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia and the T315I Mutation: 4-Year Results From OPTIC

Jorge Cortes, MD, discusses 4-year outcomes with ponatinib in patients with chronic myeloid leukemia harboring a T315I mutation.

Related Videos
Tagraxofusp Achieves Anti-tumor Activity With Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
CDAC CLL
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss ongoing research to watch in acute lymphoblastic leukemia.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss how to incorporate blinatumomab into clinical practice for ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss adverse effect management in acute lymphoblastic leukemia.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss data for blinatumomab plus chemotherapy in newly diagnosed pediatric ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss first-line treatment considerations for pediatric ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on blinatumomab as consolidation therapy in older patients with newly diagnosed ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on alloHCT outcomes from the ECOG ACRIN E1910 trial of blinatumomab.